Surgical Innovations Group PLC
25 September 2026
Surgical Innovations Group plc
(“Surgical Innovations”, the “Company”, or the “Group”)
Notice of results
Investor presentation
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery (“MIS”), announces it will release its unaudited interim results for the six months ended 30 June 2026, on Wednesday 30 September 2026.
Investor briefing
David Marsh, Chief Executive Officer, and David Anderson, Chief Financial Officer, will provide a live presentation relating to theinterim results via the Investor Meet Company platform on Wednesday 30 September at 2.15 p.m. BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00 a.m. the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meetSurgical Innovations Group plcvia:
https://www.investormeetcompany.com/surgical-innovations-group-plc/register-investor
Investors who already followSurgical Innovations Group plcon the Investor Meet Company platform will automatically be invited.
For further information please contact:
|
Surgical Innovations Group plc |
|||
|
David Marsh, CEO |
Tel: 0113 230 7597 |
||
|
David Anderson, CFO |
|
||
|
|
|
||
|
Singer Capital Markets (Nominated Adviser & Broker) |
Tel: 020 7496 3000 |
||
|
Alex Bond / Anastassiya Eley |
|
||
|
|
|
||
|
Walbrook PR (Financial PR & Investor Relations) |
Tel: 020 7933 8780 or si@walbrookpr.com |
||
|
Paul McManus / Alice Woodings |
Mob: 07980 541 893 / 07407 804 654 |
||
About Surgical Innovations Group plc
TheGroupspecialisesinthedesign,manufacture,saleanddistributionofinnovative,highqualitymedicalproducts, primarilyforuseinminimallyinvasivesurgery.Ourproductandbusinessdevelopmentisguidedandsupportedbya key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction deviceswhicharesolddirectlyintheUKhomemarketthroughoursubsidiary,ElementalHealthcare,andexported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposablealternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
Inaddition,wedesignanddevelopmedicaldevicesforcarefullyselectedOEMpartnersandhavealsocollaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
Weaimforourbrandstoberecognisedandrespectedbyhealthcareprofessionalsinallmajorgeographicalmarkets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs, theCompany’sResposableportfolioenableshealthcareproviderstoreducebothplasticwasteandtheirCO2 footprint as they strive for netzero.
Further information
Further details of the Group's businesses and products are available on the following websites:
To receive regular updates by email, please contact si@walbrookpr.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.